Taken together, our data demonstrate a synergistic effect between the separate immune targets, LAG-3 and PD-1, together, and show that higher LAG-3 and PD-1 expression in patients with DLBCL has strong inhibitory effects on CD8+ T cells. This evidence concerns the gene CD8A and diffuse large B-cell lymphoma.